GlobeNewswire·Feb 17, 2026, 8:00 AM ET

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion Therapeutics entered a settlement agreement with Alkem Laboratories Ltd. to resolve patent litigation regarding generic versions of NEXLETOL & NEXLIZET.
Under the agreement, Alkem agreed not to market generic versions of NEXLETOL or NEXLIZET in the U.S. prior to April 19, 2040, unless specific limited circumstances occur.
Pending patent litigation remains active against other defendants including Aurobindo Pharma, MSN Pharmaceuticals, Renata Limited, & Sandoz Inc.
There is no assurance regarding whether the ongoing litigation with remaining defendants will allow generic marketing prior to the April 19, 2040 date.
Esperion is a commercial-stage biopharmaceutical company focused on cardiometabolic & rare disease therapies leveraging ACLY biology.
The company markets two oral, once-daily non-statin therapies for patients at risk of cardiovascular disease & holds global approvals in over 40 countries.
Esperion is advancing its pipeline with novel product candidates for Primary Sclerosing Cholangitis & renal diseases.